← Back to Screener
Erasca, Inc. Common Stock (ERAS)
Price$21.71
Favorite Metrics
Price vs S&P 500 (26W)680.05%
Price vs S&P 500 (4W)20.71%
Market Capitalization$5.91B
All Metrics
Book Value / Share (Quarterly)$1.14
P/TBV (Annual)0.85x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)406.88%
EPS (TTM)$-0.44
10-Day Avg Trading Volume5.44M
EPS Excl Extra (TTM)$-0.44
EPS (Annual)$-0.44
ROI (Annual)-38.30%
Cash / Share (Quarterly)$0.97
ROA (Last FY)-31.44%
EBITD / Share (TTM)$-0.49
ROE (5Y Avg)-40.36%
Cash Flow / Share (Annual)$-0.34
P/B Ratio18.17x
P/B Ratio (Quarterly)3.25x
Net Income / Employee (Annual)$-1
ROA (TTM)-28.74%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)10.04x
Quick Ratio (Quarterly)9.77x
3-Month Avg Trading Volume5.61M
52-Week Price Return1524.79%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.25
52-Week High$19.78
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)-33.03%
26-Week Price Return688.80%
Quick Ratio (Annual)9.77x
13-Week Price Return128.76%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.04x
Enterprise Value$5,834.494
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.97
3-Month Return Std Dev72.30%
Net Income / Employee (TTM)$-1
ROE (Last FY)-38.30%
EPS Basic Excl Extra (Annual)$-0.44
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.44
ROI (TTM)-34.48%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.76
Price vs S&P 500 (52W)1489.69%
Year-to-Date Return411.02%
5-Day Price Return16.55%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-33.38%
Month-to-Date Return17.49%
Cash Flow / Share (TTM)$-1.57
EBITD / Share (Annual)$-0.49
ROI (5Y Avg)-40.36%
EPS Basic Excl Extra (TTM)$-0.44
P/TBV (Quarterly)1.04x
P/B Ratio (Annual)3.25x
Book Value / Share (Annual)$1.14
Price vs S&P 500 (13W)125.90%
Beta1.12x
Revenue / Share (TTM)$0.00
ROE (TTM)-34.48%
52-Week Low$1.06
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.06
4.06
4.06
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ERASErasca, Inc. Common Stock | — | — | — | — | $21.71 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Erasca is a clinical-stage oncology company developing targeted therapies for RAS/MAPK pathway-driven cancers. Its lead candidate, Naporafenib, is a pan-RAF inhibitor in development for NRAS-mutant melanoma and other RAS-driven solid tumors. The pipeline includes additional oral medications targeting downstream (ERK1/2 inhibitor) and upstream (SHP2 inhibitor) components of the RAS/MAPK pathway.